ES2528331B1 - Composición con efecto en la salud ósea y cardiovascular - Google Patents
Composición con efecto en la salud ósea y cardiovascular Download PDFInfo
- Publication number
- ES2528331B1 ES2528331B1 ES201331232A ES201331232A ES2528331B1 ES 2528331 B1 ES2528331 B1 ES 2528331B1 ES 201331232 A ES201331232 A ES 201331232A ES 201331232 A ES201331232 A ES 201331232A ES 2528331 B1 ES2528331 B1 ES 2528331B1
- Authority
- ES
- Spain
- Prior art keywords
- composition
- beta
- present
- bone
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000036996 cardiovascular health Effects 0.000 title 1
- 230000004821 effect on bone Effects 0.000 title 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 abstract description 10
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 abstract description 4
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 abstract description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 abstract description 4
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 abstract description 4
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 abstract description 4
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 abstract description 4
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 abstract description 4
- 229940076810 beta sitosterol Drugs 0.000 abstract description 4
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 abstract description 4
- 235000002360 beta-cryptoxanthin Nutrition 0.000 abstract description 4
- 239000011774 beta-cryptoxanthin Substances 0.000 abstract description 4
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 abstract description 4
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 abstract description 4
- 235000000431 campesterol Nutrition 0.000 abstract description 4
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 abstract description 4
- 229950005143 sitosterol Drugs 0.000 abstract description 4
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 abstract description 4
- 235000016831 stigmasterol Nutrition 0.000 abstract description 4
- 229940032091 stigmasterol Drugs 0.000 abstract description 4
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 abstract description 3
- VGSSUFQMXBFFTM-UHFFFAOYSA-N (24R)-24-ethyl-5alpha-cholestane-3beta,5,6beta-triol Natural products C1C(O)C2(O)CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 VGSSUFQMXBFFTM-UHFFFAOYSA-N 0.000 abstract 2
- ARYTXMNEANMLMU-UHFFFAOYSA-N 24alpha-methylcholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(C)C(C)C)C1(C)CC2 ARYTXMNEANMLMU-UHFFFAOYSA-N 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 2
- LGJMUZUPVCAVPU-JFBKYFIKSA-N Sitostanol Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC2)CC1 LGJMUZUPVCAVPU-JFBKYFIKSA-N 0.000 abstract 2
- ARYTXMNEANMLMU-ATEDBJNTSA-N campestanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]2(C)CC1 ARYTXMNEANMLMU-ATEDBJNTSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- LGJMUZUPVCAVPU-HRJGVYIJSA-N stigmastanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-HRJGVYIJSA-N 0.000 abstract 2
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 description 2
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La presente invención hace referencia a una composición que comprende beta-criptoxantina, campesterol, beta-sitosterol, estigmasterol, sitostanol, campestanol y, de al menos un excipiente farmacéuticamente aceptable. La presente invención además comprende el uso de dicha composición para la manufactura de un medicamento; en concreto de un medicamento para la prevención y/o tratamiento de osteoporosis y enfermedades cardiovasculares. Adicionalmente, la presente invención también comprende un producto comestible, preferentemente como suplemento dietético, que comprende una cantidad efectiva de beta-criptoxantina, campesterol, beta-sitosterol, estigmasterol, sitostanol, campestanol y cantidades adecuadas de otros ingredientes comestibles, para el tratamiento y/o prevención de enfermedades cardiovasculares y osteoporosis.
Description
Tabla 3. Concentraciones séricas de los compuestos durante los tratamientos
- t=0
- t=4 % de cambio t=0, t=4) Incremento neto
- Composición 1
- Beta-criptoxantina
- 16.9 (13.7-20.1) 56.5 (50.0-63.0)a 310 (222-398) 36.4 (29.9-43.0)
- Composición 2
- Beta-sitosterol
- 4.0 (3.46-4.54) 6.34 (4.7-7.98) 64.32 (34.4392.21) 10 2.36 (0.94-3.78)
- Campesterol
- 3.06 (2.7-4.20) 3.28 (2.943.62) 12.7 (4.42, 20.98) 0.29 (0.04-5.54)
- Estigmasterol
- 0.50 (0.38-0.58) 0.48 (0.380.58) 14.2 (8.06,36.46) 15 -0.01 (-0.12-0.10)
- Desmosterol
- 0.58 (0.45-0.64) 0.65 (0.59,0.71) 15.48 (8.61, 22.35) 0.07 (0.03-0.11)
- Latosterol
- 2.91 (2.47-3.35) 3.13 (2.673.59) 14.86 (2.41, 27.31) 20 0.17 (-0.16-0.50)
- Composición 3
- Beta-criptoxantina
- 17.8 (13.921.6) 53.2 (47.3-59.0)a 282 (198365) 34.5 (29.939.2)
- Beta-sitosterol
- 3.91 (3.45-4.37) 5. 46 (4.39-6.53) 49.36 (24.8173.92) 25 1.56 (0.65-2.47)
- Campesterol
- 2.91 (2.66-3.16) 3.25 (2.83-3.67) 10.75 (3.07, 18.43) 0.34 (0.08-0.60)
- Estigmasterol
- 0.5 (0.41-0.58) 0.48 (0.40-0.55) 8.94 (-8.12, 26.0) 30 -0.02 (-0.11-0.07)
- Desmosterol
- 0.62 (0.58-0.66) 0.63 (0.62-0.65) 2.91 (-3.71, 9.53) 0.01 (-0.03-0.05)
- Latosterol
- 3.21 (2.74-3.68) 3.13 (2.70-3,56) 1.29 (-7.8810.46) 35 -0.08 (-0.36-0.20)
12
Claims (1)
-
imagen1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201331232A ES2528331B1 (es) | 2013-08-06 | 2013-08-06 | Composición con efecto en la salud ósea y cardiovascular |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201331232A ES2528331B1 (es) | 2013-08-06 | 2013-08-06 | Composición con efecto en la salud ósea y cardiovascular |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2528331A1 ES2528331A1 (es) | 2015-02-06 |
| ES2528331B1 true ES2528331B1 (es) | 2015-12-02 |
Family
ID=52440049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES201331232A Active ES2528331B1 (es) | 2013-08-06 | 2013-08-06 | Composición con efecto en la salud ósea y cardiovascular |
Country Status (1)
| Country | Link |
|---|---|
| ES (1) | ES2528331B1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080305096A1 (en) * | 2007-06-07 | 2008-12-11 | Unicity International, Inc. | Method and composition for providing controlled delivery of biologically active substances |
| US20090264520A1 (en) * | 2008-04-21 | 2009-10-22 | Asha Lipid Sciences, Inc. | Lipid-containing compositions and methods of use thereof |
-
2013
- 2013-08-06 ES ES201331232A patent/ES2528331B1/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2528331A1 (es) | 2015-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008003582A1 (es) | Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash). | |
| JP2010522190A5 (es) | ||
| ES2659353T3 (es) | Métodos y formulaciones nutricionales para aumentar la eficacia y reducir los efectos secundarios del tratamiento del cáncer | |
| RU2018138995A (ru) | Способы индуцирования и пролонгирования насыщения, уменьшения объёма и поглощения пищи, контроля веса и стимулирования снижения веса, пищевая композиция | |
| RU2018136872A (ru) | Композиции, содержащие 15-oh эпк, и способы их применения | |
| CL2007001945A1 (es) | Compuestos derivados de alquilpiridazina, inhibidores de 11 beta-hsd1; proceso de obtencion de los compuestos; composicion farmaceutica que los comprenden; y usos en el tratamiento de la diabetes, obesidad, trastorno de ingestion de comida, dislipide | |
| PH12018000207B1 (en) | A pharmaceutical composition for prevention of diet induced obesity | |
| EP2575456A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ECCHYMOSIS | |
| ES2528331B1 (es) | Composición con efecto en la salud ósea y cardiovascular | |
| WO2011126342A3 (ko) | 대잎둥굴레 또는 층층갈고리둥굴레 추출물의 신규한 용도 | |
| WO2007121545A8 (en) | S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions | |
| RU2013133998A (ru) | Способы и композиции для предотвращения и лечения остеоартрита | |
| BR112012013207A2 (pt) | método para produzir uma bebida/produto alimentício tendo um aroma e/ou sabor aprimorado, composição para conferir aroma e/ou sabor, produto alimentício, e, métodos para aprimorar um aroma e/ou um sabor de um produto alimentício e para produzir um produto alimentício tendo um aroma e/ou sabor aprimorado. | |
| ES2446494B1 (es) | Aplicación terapéutica de necrostatina-1 en esteatohepatitis | |
| WO2018078599A3 (en) | Composition for the preventive or curative treatment of liver disorders | |
| CN102771598A (zh) | 防治咽喉炎、鼻窦炎的木蝴蝶代茶饮品 | |
| Mafra | Nutritional strategies to reduce inflammation in chronic kidney disease patients | |
| IL204957A (en) | Derivatives of 3 - (aminoalkoxyimino) - androstane and androsten | |
| CN106552252A (zh) | 一种退热酒及其制备方法 | |
| EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) | Scientific Opinion on the substantiation of a health claim related to a combination of diosmin, troxerutin and hesperidin and maintenance of normal venous‐capillary permeability pursuant to Article 13 (5) of Regulation (EC) No 1924/2006 | |
| MX2019015712A (es) | Formas cristalinas de beta-sitosterol. | |
| Hurtado Barroso et al. | Comparison of urinary excretion of total polyphenols after a high antioxidant diet and a low antioxidant diet | |
| CN104027422B (zh) | 一种中药减肥保健酒及其制备方法 | |
| Hansen | The clinical diagnosis of acute rhinosinusitis and its therapeutic consequences | |
| RU2013154562A (ru) | Способы и композиции для сохранения безжировой массы тела в процессе похудения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 2528331 Country of ref document: ES Kind code of ref document: B1 Effective date: 20151202 |
|
| PC2A | Transfer of patent |
Owner name: HERO, AG Effective date: 20230127 |
|
| PC2A | Transfer of patent |
Owner name: MARIA ELENA HERNANDEZ ALVAREZ Effective date: 20240626 |